Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708
Debt
Debt-to-Equity Ratio1.48
Current Ratio2.34
Quick Ratio2.34
Price-To-Earnings
Trailing P/E Ratio-1.00
Forward P/E Ratio-1.34
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book3.11
Profitability
EPS (Most Recent Fiscal Year)($2.06)
Net Income$-221,570,000.00
Net MarginsN/A
Return on Equity-228.85%
Return on Assets-114.90%
Miscellaneous
Employees45
Outstanding Shares122,080,000
Market Cap$252.71 million
Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions
What is Axovant Sciences' stock symbol?
Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."
How were Axovant Sciences' earnings last quarter?
Axovant Sciences Ltd (NASDAQ:AXON) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.33. View Axovant Sciences' Earnings History.
When is Axovant Sciences' next earnings date?
What price target have analysts set for AXON?
10 brokers have issued twelve-month target prices for Axovant Sciences' shares. Their predictions range from $4.00 to $30.00. On average, they expect Axovant Sciences' share price to reach $12.6667 in the next year. This suggests a possible upside of 517.9% from the stock's current price. View Analyst Price Targets for Axovant Sciences.
What is the consensus analysts' recommendation for Axovant Sciences?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Axovant Sciences.
What are Wall Street analysts saying about Axovant Sciences stock?
Here are some recent quotes from research analysts about Axovant Sciences stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (8/13/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to the achievement of target price. Our price target of $7/share is based on an equally-weighted composite of: (a) $6.27/share, as a 35x multiple of taxed and diluted $2.30 discounted back to FY18 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $7.26/share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2018)
- 3. Chardan Capital analysts commented, "We now assign an incremental $2/share of value to AXON based on AXON capturing some of this value. We expect Oxford BioMedica striking new partnerships in the GT space will provide further upside to shares from here. We note that Axovant has strengthened its management with the addition of gene therapy experts to its leadership. Axovant announced the addition of Dr. Michael Hayden as Chairman of its SAB. Dr. Hayden “played a key role in the discovery and development of Glybera”. With this deal, Axovant announced its new CTO will be Dr. Fraser Wright, the co-founder and former CTO of Spark Therapeutics (Buy)." (6/6/2018)
- 4. Cowen Inc analysts commented, "We maintain our BUY rating and $25 PT for SVRA shares." (2/13/2018)
Are investors shorting Axovant Sciences?
Axovant Sciences saw a increase in short interest in July. As of July 13th, there was short interest totalling 4,928,644 shares, an increase of 27.1% from the June 29th total of 3,878,886 shares. Based on an average daily trading volume, of 3,189,249 shares, the days-to-cover ratio is presently 1.5 days. Approximately 27.6% of the shares of the stock are sold short. View Axovant Sciences' Current Options Chain.
Who are some of Axovant Sciences' key competitors?
Some companies that are related to Axovant Sciences include Assembly Biosciences (ASMB), TG Therapeutics Inc common stock (TGTX), Revance Therapeutics (RVNC), Tricida (TCDA), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Amarin (AMRN), Dynavax Technologies (DVAX), Amphastar Pharmaceuticals (AMPH), OptiNose (OPTN), Dicerna Pharmaceuticals (DRNA) and Cara Therapeutics (CARA).
Who are Axovant Sciences' key executives?
Axovant Sciences' management team includes the folowing people:
- Dr. Gregory M. Weinhoff, Chief Financial Officer (Age 47)
- Dr. Pavan Cheruvu, Chief Exec. Officer
- Mr. Michael Adasczik, Principal Accounting Officer (Age 44)
- Mr. Jonathan Neely, Head of Investor Relations & Corp. Communications
- Ms. Marianne L. Romeo Dinsmore, Head of Global Transactions & Risk Management (Age 50)
When did Axovant Sciences IPO?
(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Has Axovant Sciences been receiving favorable news coverage?
News stories about AXON stock have been trending somewhat positive on Sunday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axovant Sciences earned a news impact score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Axovant Sciences.
Who are Axovant Sciences' major shareholders?
Axovant Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include DEXXON HOLDINGS LTD. (73.10%), LO ANDREW (73.10%), QVT FINANCIAL LP (73.10%), SVF INVESTMENTS (UK) LTD (73.10%), VIKING GLOBAL INVESTORS LP (73.10%) and MACHADO PATRICK (73.10%). Company insiders that own Axovant Sciences stock include David Hung, George Bickerstaff, Global Investors Lp Viking and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.
Which major investors are selling Axovant Sciences stock?
Which major investors are buying Axovant Sciences stock?
AXON stock was purchased by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Paloma Partners Management Co, GSA Capital Partners LLP and Tower Research Capital LLC TRC . Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, George Bickerstaff, Global Investors Lp Viking and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.
How do I buy shares of Axovant Sciences?
Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axovant Sciences' stock price today?
One share of AXON stock can currently be purchased for approximately $2.05.
How big of a company is Axovant Sciences?
Axovant Sciences has a market capitalization of $252.71 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Axovant Sciences employs 45 workers across the globe.
How can I contact Axovant Sciences?
Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.
MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
